Physician profile
Igor Gosev
NPI 1598033649
$118,244.04
in general payments reported to CMS, 2019-2025
15 companies · $4,650 in 2025
The $4,650 reported for 2025 was more than what 81% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $26K · 2021: $4,104 · 2022: $14K · 2023: $18K · 2024: $21K · 2025: $4,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Travel and Lodging: $13K · Food and Beverage: $7,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,637.00 |
| Travel and Lodging | $12,504.55 |
| Food and Beverage | $7,439.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $101,265.56 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Thoratec Heartmate 3 |
| Lsi Solutions INC | $9,403.93 | 2019-2022 | |
| Abiomed | $2,192.16 | 2019-2025 | Impella |
| Cvrx, INC. | $2,149.66 | 2023-2025 | Barostim Neo System |
| Atricure, INC. | $2,075.06 | 2019-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Atricure Cryoice Cryoablation System (Cryo2) |
| Arthrex, INC. | $405.71 | 2024 | |
| Seapearl East, INC | $400.42 | 2024 | |
| Zimmer Biomet Holdings, INC. | $137.18 | 2021 | |
| Medtronic Vascular, INC. | $77.59 | 2020 | |
| Briohealth Solutions, INC. | $34.70 | 2025 | Briovad |
| Avanos Medical | $28.24 | 2025 | Cortrak |
| Endotronix, INC. | $21.30 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| La Jolla Pharmaceutical Company | $19.98 | 2025 | Giapreza |
| Merck Sharp & Dohme LLC | $17.43 | 2025 | Verquvo |
| Invivyd INC | $15.12 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Gosev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.